Previous 10 |
home / stock / knbwy / knbwy news
The following slide deck was published by Kirin Holdings Company, Limited in conjunction with their 2022 Q1 earnings call. For further details see: Kirin Holdings Company, Limited 2022 Q1 - Results - Earnings Call Presentation
Kirin Holdings Company press release (OTCPK:KNBWY): Q1 GAAP EPS of ¥29.84. Revenue of ¥87.75B (+8.2% Y/Y). For further details see: Kirin Holdings Company GAAP EPS of ¥29.84, revenue of ¥87.75B
Molson Coors represents a bargain play in the nearly recession-proof alcoholic beverage industry. A nearly 3% dividend and 9% free cash flow yield are available to intelligent investors (roughly double the prevailing S&P 500 rates). Technical trading momentum has improved dram...
Early indications show that Kyowa Kirin has a blockbuster drug with KHK4083, a treatment for severe atopic dermatitis (eczema). Phase 2 trials have shown encouraging results and the agreement to jointly develop and commercialize the drug with Amgen is a positive signal. With both ...
The Beer Tax Unification Act will damage Kirin's competitive pricing in the beer-substitute market for the medium to long term. Kirin's 53.8% stake in pharmaceutical company Kyowa Kirin causes problems over parent attributable net income and free cash flow disclosure. The shares a...
With the pandemic impacting most of the economic sectors, the beer sector contracted 3% between 2019 and 2020 and it experienced its first production decline.However, number of new breweries have climbed to all-time high (8,764 in 2020); as per Craft Brewing Industry Production Report...
Kirin management has done a commendable job with the domestic brewing business, particularly on product development, but the Japanese market doesn't offer much growth. Management is pivoting hard toward nutritional and "wellness" products, and looking to leverage a large investment in...
News, Short Squeeze, Breakout and More Instantly...
Kirin Holdings Co Ltd ADR Company Name:
KNBWY Stock Symbol:
OTCMKTS Market:
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
ESSA Pharma Inc. (EPIX) is expected to report $-0.17 for Q1 2024 QuidelOrtho Corp Com (QDEL) is expected to report $2.01 for Q4 2023 FaZe Holdings Inc. (FAZE) is expected to report for Q4 2023 Portsmouth Square, Inc. (PRSI) is expected to report for Q2 2024 Similarweb Ltd. (SMWB) ...
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...